prof. dr. ir. Steven Goossens
- Work address
-
C. Heymanslaan 10, ingang 22 - verdieping 2
9000 Gent - Steven.Goossens@UGent.be
- ORCID iD
-
0000-0002-5693-8570
Show
Sort by
-
RRM2 enhances MYCN-driven neuroblastoma formation and acts as a synergistic target with CHK1 inhibition
-
In vivo stabilization of a less toxic asparaginase variant leads to a durable anti-tumor response in acute leukemia
-
- Journal Article
- A1
- open access
MEF2C opposes Notch in lymphoid lineage decision and drives leukemia in the thymus
-
Distinct transcriptional programs in ascitic and solid cancer cells induce different responses to chemotherapy in high-grade serous ovarian cancer
-
- Journal Article
- A1
- open access
Myb drives B-cell neoplasms and myeloid malignancies in vivo
-
- Journal Article
- A1
- open access
Novel insights on the use of L-asparaginase as an efficient and safe anti-cancer therapy
-
Direct and indirect anti-leukemic properties of Activity-on-Target interferons for the treatment of T-cell acute lymphoblastic leukemia
-
Epithelial-mesenchymal transition (EMT) as a therapeutic target
-
SOX11 functions as an oncogene in Lmo2-driven T-cell lymphoblastic leukemia (T-ALL)
-
- Journal Article
- A1
- open access
Unlike its paralog LEDGF/p75, HRP-2 is dispensable for MLL-R leukemogenesis but important for leukemic cell survival